Highlights
• Genus described a solid start to its financial year in an update covering four months to October.
• The animal genetics group expects FY27 adjusted profit before tax in line with current market expectations.
• PIC, the pig genetics business, traded resiliently thanks to its royalty-based model and good product performance.
• Genus appointed Shar Nebhrajani as a non-executive director, with her appointment taking effect on 1 January 2027.
How has the pig and cattle genetics specialist begun its new financial year? Genus (LSE:GNS) answered that question at its Annual General Meeting today, calling the first four months a solid start and confirming that full-year profit expectations remain on track. A separate statement added a new non-executive director to the board.
Inside the AGM trading statement
The update covers the four months ended 31 October 2026 and was issued to coincide with the AGM at 11am. Genus (LSE:GNS) expects adjusted profit before tax for the year to June 2027, measured in constant currency, to be in line with current market expectations. As previously guided, profits are expected to be weighted towards the second half. A footnote sets out the company-compiled consensus range of £91.0 million to £94.5 million, drawn from 13 analyst estimates.
PIC and ABS: two divisions, two trends
PIC, the porcine genetics division, has traded resiliently, even as its customers face difficult end-markets. Genus (LSE:GNS) attributes that performance to its royalty-based Business model, good product performance and long-standing customer relationships. ABS, the dairy and beef genetics business, has seen low global dairy prices weigh on customer profitability. Management expects a material improvement in ABS during the second half, supported by commercial and operational initiatives already under way.
Currency effects on reported numbers
Guidance is given in constant currency, which strips out exchange-rate movements. Genus notes that weaker Brazilian real and Mexican peso rates against sterling are expected to have an adverse effect of £3 million to £4 million on the year, if current exchange rates persist. For shareholders, that means reported profit can differ from the constant-currency figure that anchors the guidance. The update also refers to the PRRS-resistant pig, which the group plans to commercialise once regulatory approvals are obtained.
New non-executive director joins the board
In a second announcement, Genus said Sharmila (Shar) Nebhrajani will join as a non-executive director from 1 January 2027. A Chartered Accountant, she chairs the National Institute for Health and Care Excellence and is senior independent director and audit committee chair at Halma. She also chairs the remuneration committee at ITV and sits on the Essentra board, and will step down from the Severn Trent board on 30 November 2026. Her career spans public health, medical science, government and the non-profit sector, and she holds an MA in Physiological Sciences from Oxford University. The appointment followed a process run by an external search agency. Chair Iain Ferguson said: "We are delighted to welcome Shar to the Board." He described her as "a highly experienced non-executive director and audit committee chair".
Dates on the investor calendar
Interim results for the six months to 31 December 2026 are scheduled for 25 February 2027. That release should show how the expected second-half weighting and the ABS initiatives are progressing. For those tracking healthcare-adjacent and agricultural science names on the UK stock market, currency movements and regulatory progress on the PRRS-resistant pig remain the other items to follow.
How the Royalty model works
Genus attributes the resilience of PIC, its pig genetics division, to a royalty-based business model. Under such a model the group earns income linked to the performance of the animals its genetics produce, rather than from a one-off sale, which helps explain why PIC traded resiliently while its customers faced difficult end-markets. ABS, the dairy and beef genetics business, has seen low global dairy prices weigh on customer profitability, and management expects a material improvement in the second half supported by commercial and operational initiatives already under way. The two divisions therefore illustrate how end-market conditions can differ within a single group.
Constant currency and the consensus range
Guidance is given in constant currency, which strips out exchange-rate movements. Genus noted that weaker Brazilian real and Mexican peso rates against sterling are expected to have an adverse effect of £3 million to £4 million on the year if current rates persist. The footnote in the update quotes a company-compiled consensus range of £91.0 million to £94.5 million for adjusted profit before tax, drawn from 13 analyst estimates, which gives readers a reference for market expectations. Interim results for the six months to 31 December 2026 are scheduled for 25 February 2027, and the PRRS-resistant pig will be commercialised once regulatory approvals are obtained.






Please wait processing your request...